Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2

被引：0
|
作者：
Langley, Richard G. [1 ]
Gooderham, Melinda [2 ]
Papp, Kim Alexander [3 ,4 ]
Yamauchi, Paul [5 ]
Thaci, Diamant [6 ]
Parno, Jeff [7 ]
Mendelsohn, Alan M. [7 ]
Rozzo, Stephen J. [7 ]
Menter, Alan [8 ]
机构：
[1] Dalhousie Univ, Div Dermatol, Dept Med, Halifax, NS, Canada
[2] SKin Ctr Dermatol, Ft Lauderdale, FL USA
[3] Prob Med Res, Waterloo, ON, Canada
[4] K Papp Clin Res, Waterloo, ON, Canada
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Univ Lubek, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[7] Sun Pharmaceut Ind, Princeton, NJ USA
[8] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15910
引用
收藏
页码：AB163 / AB163
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
    Crowley, Jeffrey
    Korman, Neil J.
    Spelman, Lynda
    Igarashi, Atsuyuki
    Gupta, Aditya K.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Eads, Kimberly M.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB162 - AB162
  • [2] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
    Gooderham, M.
    Papp, K.
    Blauvelt, A.
    Thaci, D.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
  • [3] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [4] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [5] Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 398 - 407
  • [6] Efficacy of long-term tildrakizumab for plaque psoriasis: PASI 50/75/90/100 and PGA for up to 5 years of treatment in reSURFACE 2
    Roebuck, Heather
    Farberg, Aaron S.
    Hanna, Sameh
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB80 - AB80
  • [7] Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions of 2 phase 3 studies
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Papp, K. A.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Li, Q.
    Green, S.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 110 - 111
  • [8] Efficacy of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions to 2 phase 3 clinical studies
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Green, S.
    Li, Q.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 108
  • [9] Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
    Warren, Richard
    Sofen, Howard
    Imafuku, Shinichi
    Szepietowski, Jacek C.
    Blauvelt, Andrew
    Spelman, Lynda
    Toms, Jessica
    Buck, Alex
    Banerjee, Subhashis
    Menter, Alan
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4230 - 4232
  • [10] Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
    Spelman, Lynda
    Warren, Richard B.
    Sofen, Howard
    Imafuku, Shinichi
    Blauvelt, Andrew
    Toms, Jessica
    Buck, Alex
    Banerjee, Subhashis
    Menter, Alan
    Szepietowski, Jacek C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 28
12345